Kite Pharma (KITE) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $80 and the lowest price target forecast is $60. The average forecast of all the analysts is $71.5 and the expected standard deviation is $7.52.
Kite Pharma (KITE) : The consensus on Kite Pharma (KITE) based on 9 analyst recommendation on the company stock is 1.33, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Also, Equity analysts at the Brokerage firm Barclays maintains its rating on Kite Pharma (NASDAQ:KITE). The rating major has initiated the coverage with equal-weight rating on the shares. The Analysts at Barclays raises the price target from $58 per share to $60 per share. The rating by the firm was issued on August 9, 2016.
Kite Pharma (NASDAQ:KITE): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $57.53 and $57.00 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $58.96. The buying momentum continued till the end and the stock did not give up its gains. It closed at $58.87, notching a gain of 2.17% for the day. The total traded volume was 358,434 . The stock had closed at $57.62 on the previous day.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Companys lead product candidate KTE-C19, is a CAR-based therapy, for the treatment of refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR, KTE-C19CAR and EGFRvlll CAR, among others.